Biotechnology News

加利福尼亚州阿拉米达, July 08, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI)（简称 “Vivani” 或“公司”）是一家开发新型超长效药物植入剂的创新型生物制药公司，今日宣布与 Novo Nordisk 签署一项新协议，授权 Novo Nordisk 评估旗下司美格鲁肽药物植入剂 NPM-139。依托...

加州阿拉米達, July 08, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI)（簡稱「Vivani」或「該公司」）是致力於開發新型超長效藥物植入劑的創新生物製藥公司，今天宣佈與 Novo Nordisk 簽署一份新協議，允許 Novo Nordisk 為該公司的司美格魯肽 (semaglutide) 藥物植入劑...

ALAMEDA, California, July 08, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” atau “Perusahaan”), perusahaan biofarmasi inovatif yang mengembangkan implan obat baru dengan...

カリフォルニア州アラメダ発 , July 08, 2026 (GLOBE NEWSWIRE) --  新規の超長時間作用型薬剤インプラントを開発する革新的なバイオ医薬品企業、ヴィヴァニ・メディカル (Vivani Medical, Inc.) (NASDAQ: VANI) (以下「ヴィヴァニ」または「同社」) は本日、ノボ ノルディスク (Novo Nordisk)...

เมืองอลาเมดา รัฐแคลิฟอร์เนีย, July 08, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” หรือ “บริษัท”)...

미국 캘리포니아주 알라메다, July 08, 2026 (GLOBE NEWSWIRE) -- 혁신적인 초장기 지속형 약물 임플란트를 개발하는 바이오의약품 기업 Vivani Medical, Inc.(나스닥: VANI)는 Novo Nordisk와 새로운 계약을 체결했다고 밝혔다. 이번 계약에 따라 Novo Nordisk는 Vivani가 개발 중인...

ALAMEDA, California, July 08, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” atau “Syarikat”), sebuah syarikat biofarmaseutikal inovatif yang membangunkan implan ubat jangka...

TAIPEI, July 07, 2026 (GLOBE NEWSWIRE) -- TaiMed Biologics (TPEX: 4147) announced today that its HIV therapy Trogarzo (ibalizumab; English name: Trogarzo Injection; Chinese name: 佐加洛注射劑) has...

Richard Lowenthal, Chief Executive Officer, Transitioning following More than a Decade of Leadership Since Co-Founding the Company Donn Casale, President, Appointed Chief Executive Officer and...

CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of...